Calm in a room: can sensory therapy soothe the mind?
NCT ID NCT07748078
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether Snoezelen therapy—a calming, multisensory experience using lights, sounds, and textures—can improve health in adults with schizophrenia (including those needing institutional care) and women with alcohol dependence. Participants will attend 30-minute sessions twice a week for 6 or 12 weeks. Researchers will measure changes in cognition, mood, anxiety, life satisfaction, daily functioning, and certain blood markers to see if this gentle therapy offers benefits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Snoezelen therapy, a multisensory relaxation intervention involving controlled visual, auditory, and tactile stimuli in a calming environment
- What this could lead to
- If effective, Snoezelen therapy could offer a drug-free, non-invasive way to ease symptoms and improve quality of life for people with schizophrenia or alcohol dependence.
- What could go wrong
- This is an early-stage trial with a modest number of participants, and results may not generalize. The therapy is supportive, not curative, and its benefits may vary widely between individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 140 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1. Adults suffering from schizophrenia requiring permanent institutional care, N=40 Inclusion criteria: * women and men aged ≥ 18 years, * consent of the patient or legal guardian to participate in the study, * schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms, * stable drug therapy (treatment unchanged for at least 3 months) * ability to understand and follow the therapist's instructions, * functional ability of everyday life on the Barthel scale below 40 points, Exclusion criteria: * lack of consent to participate in the study; * pregnancy; * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; * diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs. 2. Adults (men) suffering from schizophrenia, N=40 Inclusion criteria: * men aged ≥ 18 years, * consent of the patient or legal guardian to participate in the study, * clinically confirmed schizophrenia with predominance of negative symptoms, * stable drug therapy (treatment unchanged for at least 1 month), * ability to understand and follow the therapist's instructions, * functional ability of everyday life on the Barthel scale above 40 points, Exclusion criteria: * lack of consent to participate in the study; * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system disturbing body balance and limb mobility. 3. Adults (women) addicted to alcohol, N= 60 Inclusion criteria: * female gender; * age ≥ 18 years; * consent of the patient or legal guardian to participate in the study; * alcohol dependence syndrome (F10.2 according to ICD-10); * history of depressive and anxiety symptoms; * ability to understand and follow the therapist's instructions; * functional ability of everyday life on the Barthel scale above 40 points. Exclusion criteria: * lack of consent to participate in the study; * pregnancy; * psychoactive substances other than alcohol; * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.); * mental illnesses other than depression and anxiety disorders; * psychotic diseases (F20- schizophrenia and other schizophrenic disorders); * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient); * unstable or untreated epilepsy, based on EEG; * active cancer disease; * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; * severe cognitive impairment; * diagnosis of autism and ADHD; * PTSD; * intellectual disability (diagnosis F70 - F79); * diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol dependence (primary condition) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland
Rybnik, Silesian Voivodeship, 44-200, Poland
-
Jerzy Kukuczka Academy of Physical Education in Katowice, Poland
Katowice, Silesian Voivodeship, 40-065, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Brain-Training games rewire the mind to fight alcohol addiction?
- Can a Stress-Hormone blocker take the edge off alcohol?
- Scientists build a computer model of the brain to explain hearing voices
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms